stockrowGilead Sciences, Inc. (GILD) vs Johnson & Johnson (JNJ)
- Gilead Sciences, Inc. GILD 167.46 −4.02%
- Johnson & Johnson JNJ 272.44 −1.40%
Gilead Sciences, Inc. and Johnson & Johnson are both Drug Manufacturers General companies. Johnson & Johnson is the larger, with a market value of $655.6B against $207.8B — 3.2× the size. Gilead Sciences, Inc. has negative trailing earnings, so its P/E is not meaningful; Johnson & Johnson trades at 41.3×. Johnson & Johnson grew revenue faster over the last twelve months: 7.80% against 6.54%. Johnson & Johnson has the higher net margin (16.2% vs −12.5%) and the higher return on invested capital (11.1% vs −4.51%). Both pay a dividend; Gilead Sciences, Inc. yields more (1.94% vs 1.94%). Across the 21 metrics below, Johnson & Johnson leads on 13 and Gilead Sciences, Inc. on 8.
Valuation
Profitability
| Metric | GILD | JNJ | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 79.93% | 67.56% | 73.01% |
| Operating margin | (7.63%) | 19.72% | 18.34% |
| Net margin | (12.47%) | 16.20% | 7.31% |
| Free cash flow margin | 44.47% | 21.13% | 18.52% |
| Return on equity | (22.45%) | 20.02% | 5.80% |
| Return on assets | (7.03%) | 8.25% | 2.28% |
| Return on invested capital | (4.51%) | 11.07% | 6.26% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack